Inmune Bio (INMB) EBITDA Margin (2021 - 2025)
Historic EBITDA Margin for Inmune Bio (INMB) over the last 5 years, with Q1 2025 value amounting to 19548.0%.
- Inmune Bio's EBITDA Margin rose 582734300.0% to 19548.0% in Q1 2025 from the same period last year, while for Sep 2025 it was 99230.0%, marking a year-over-year decrease of 2466700.0%. This contributed to the annual value of 298985.71% for FY2024, which is 2795612000.0% down from last year.
- Per Inmune Bio's latest filing, its EBITDA Margin stood at 19548.0% for Q1 2025, which was up 582734300.0% from 77821.43% recorded in Q1 2024.
- In the past 5 years, Inmune Bio's EBITDA Margin registered a high of 4201.23% during Q1 2022, and its lowest value of 113875.0% during Q1 2021.
- Its 5-year average for EBITDA Margin is 33253.56%, with a median of 19548.0% in 2025.
- Per our database at Business Quant, Inmune Bio's EBITDA Margin soared by 1096737700bps in 2022 and then crashed by -605977400bps in 2024.
- Inmune Bio's EBITDA Margin (Quarter) stood at 5860.12% in 2021, then rose by 5bps to 5556.7% in 2022, then crashed by -445bps to 30257.14% in 2023, then tumbled by -157bps to 77821.43% in 2024, then skyrocketed by 75bps to 19548.0% in 2025.
- Its EBITDA Margin was 19548.0% in Q1 2025, compared to 77821.43% in Q1 2024 and 30257.14% in Q4 2023.